Evidence map›Paper›PMID 36419492›Full record

ArticleFrontiers in cardiovascular medicine2022

Vein morphometry in end-stage kidney disease: Teasing out the contribution of age, comorbidities, and vintage to chronic wall remodeling.

Xochilt Labissiere, Zachary M Zigmond, Akshara Challa, Christopher Montoya, Karen Manzur-Pineda, Amalia Abraham, Marwan Tabbara, Alghidak Salama, Yue Pan, Loay H Salman and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Human Data First: New Biological Premises for Arteriovenous Fistula Research.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Xochilt LabissiereDeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Zachary M ZigmondBruce W. Carter Veterans Affairs Medical Center, Miami, FL, United States.
Akshara ChallaDeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Christopher MontoyaDeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Karen Manzur-PinedaDeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Amalia AbrahamDeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Marwan TabbaraDeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Alghidak SalamaDeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Yue PanDepartment of Public Health Sciences, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Loay H SalmanDivision of Nephrology, Albany Medical College, Albany, NY, United States.
Xiaofeng YangLewis Katz School of Medicine, Temple University, Philadelphia, PA, United States.
Roberto I Vazquez-PadronDeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Laisel MartinezDeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
University of Miami · USBruce W. Carter VA Medical Center · USAlbany Medical Center Hospital · USTemple University · US

Funding

The Role of Vascular Calprotectin in Arteriovenous Fistula MaturationR01DK132888 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Roberto Irenardo Vazquez Padron · 2022 to 2026
$2.1M
Dual Role of Lysyl Oxidase in Arteriovenous Fistula FailureR01DK121227 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SHIU, YAN-TING E., VAZQUEZ PADRON, ROBERTO IRENARDO · 2019 to 2023
$2.1M
Vascular Progenitor Cells in Arteriovenous Fistula StenosisR01DK098511 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ANDREOPOULOS, FOTIOS MATTHAIOS, SALMAN, LOAY HATEM · 2013 to 2016
$1.5M
Cellular Mechanisms of Mac-1 Mediated AtheroprotectionK08HL151747 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARTINEZ, LAISEL · 2020 to 2024
$575k
The Multiple Roles of Lysyl Oxidase in Arteriovenous Fistula FailureI01BX004658 · VA · MIAMI VA HEALTH CARE SYSTEM · PI VAZQUEZ PADRON, ROBERTO IRENARDO · 2020 to 2023
–
BLRD VA I01 BX004658NHLBI NIH HHS K08 HL151747NIDDK NIH HHS R01 DK098511NIDDK NIH HHS R01 DK121227NIDDK NIH HHS R01 DK132888
6 · The paper itself

Abstract

Background: Chronic kidney disease (CKD) is a highly comorbid condition with significant effects on vascular health and remodeling. Upper extremity veins are important in end-stage kidney disease (ESKD) due to their potential use to create vascular accesses. However, unlike arteries, the contribution of CKD-associated factors to the chronic remodeling of veins has been barely studied. Methods: We measured morphometric parameters in 315 upper extremity veins, 131 (85% basilic) from stage 5 CKD/ESKD patients and 184 (89% basilic) from non-CKD organ donors. Associations of demographic and clinical characteristics with intimal hyperplasia (IH) and medial fibrosis were evaluated using multivariate regression models. Results: The study cohort included 33% females, 30% blacks, 32% Hispanics, and 37% whites. Over 60% had hypertension, and 25% had diabetes independent of CKD status. Among kidney disease participants, 26% had stage 5 CKD, while 22 and 52% had ESKD with and without history of a previous arteriovenous fistula/graft (AVF/AVG), respectively. Intimal hyperplasia was associated with older age (β = 0.13 per year, confidence interval [CI] = 0.002-0.26), dialysis vintage > 12 months (β = 0.22, CI = 0.09-0.35), and previous AVF/AVG creation (β = 0.19, CI = 0.06-0.32). Upper quartile values of IH were significantly associated with diabetes (odds ratio [OR] = 2.02, CI = 1.08-3.80), which demonstrated an additive effect with previous AVF/AVG history and longer vintage in exacerbating IH. Medial fibrosis also increased as a function of age (β = 0.17, CI = 0.04-0.30) and among patients with diabetes (β = 0.15, CI = 0.03-0.28). Age was the predominant factor predicting upper quartile values of fibrosis (OR = 1.03 per year, CI = 1.01-1.05) independent of other comorbidities. Conclusion: Age and diabetes are the most important risk factors for chronic development of venous IH and fibrosis independent of CKD status. Among kidney disease patients, longer dialysis vintage, and history of a previous AVF/AVG are strong predictors of IH.

Indexed as

chronic kidney diseasediabetesfibrosisintimal hyperplasia (IH)vascular aging

Identifiers

PMID36419492
PMCPMC9676677
OpenAlexW4308322062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.